Immunological markers for PML prediction in MS patients treated with natalizumab

Frontiers in Immunology

Volumn 6, Issue JAN, 2015, Pages

  Antoniol, Caroline ^a,b   Stankoff, Bruno ^a,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Effector memory T cells; JC virus; Multiple sclerosis; PML; Risk stratification; Selectin

Indexed keywords

EID: 84926667904     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00668     Document Type: Review

References (77)

1. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 354:899-910. doi:10.1056/NEJMoa044397
2. Brew BJ, Davies NWS, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 6:667-79. doi:10.1038/nrneurol.2010.164
3. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 354:924-33. doi:10.1056/NEJMoa054693
4. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med (2005) 353:375-81. doi:10.1056/NEJMoa051847
5. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med (2005) 353:369-74. doi:10.1056/NEJMoa051782
6. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 353:362-8. doi:10.1056/NEJMoa051586
7. Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology (2013) 80:1430-8. doi:10.1212/WNL.0b013e31828c2fa1
8. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue E-W, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2012) 72:779-87. doi:10.1002/ana.23676
9. Mc Govern EM, Hennessy MJ. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. J Neurol (2013) 260:665-7. doi:10.1007/s00415-012-6759-0
10. Phan-Ba R, Lommers E, Tshibanda L, Calay P, Dubois B, Moonen G, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry (2012) 83:224-6. doi:10.1136/jnnp-2011-300511
11. Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry (2014). doi:10.1136/jnnp-2014-308630
12. Lindå H, von Heijne A. Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol (2013) 4:11. doi:10.3389/fneur.2013.00011
13. Iacobaeus E, Ryschkewitsch C, Gravell M, Khademi M, Wallstrom E, Olsson T, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler (2009) 15:28-35. doi:10.1177/1352458508096870
14. Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2014) 76(6):792-801. doi:10.1002/ana.24153
15. Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 18:143-52. doi:10.1177/1352458511435105
16. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol (2010) 9:425-37. doi:10.1016/S1474-4422(10)70040-5
17. de Goër de Herve M-G, Dembele B, Vallée M, Herr F, Cariou A, Taoufik Y. Direct CD4 help provision following interaction of memory CD4 and CD8 T cells with distinct antigen-presenting dendritic cells. J Immunol (2010) 1950(185):1028-36. doi:10.4049/jimmunol.0904209
18. Gasnault J, Kahraman M, de Goër de Herve MG, Durali D, Delfraissy J-F, Taoufik Y. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS (2003) 17:1443-9. doi:10.1097/00002030-200307040-00004
19. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifoca leukoencephalopathy. Brain J Neurol (2004) 127:1970-8. doi:10.1093/brain/awh215
20. Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler (2011) 17:151-6. doi:10.1177/1352458510385834
21. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol (2008) 64:379-87. doi:10.1002/ana.21443
22. Tan CS, Ellis LC, Wüthrich C, Ngo L, Broge TA, Saint-Aubyn J, et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol (2010) 84:9200-9. doi:10.1128/JVI.00609-10
23. Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, et al. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group". Mult Scler (2013) 19:1213-5. doi:10.1177/1352458512466165
24. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis (2009) 199:837-46. doi:10.1086/597126
25. Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis (2011) 204:237-44. doi:10.1093/infdis/jir256
26. Bellizzi A, Anzivino E, Rodio DM, Cioccolo S, Scrivo R, Morreale M, et al. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol J (2013) 10:298. doi:10.1186/1743-422X-10-298
27. Skarica M, Eckstein C, Whartenby KA, Calabresi PA. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol (2011) 235:70-6. doi:10.1016/j.jneuroim.2011.02.010
28. Sottini A, Capra R, Zanotti C, Chiarini M, Serana F, Ricotta D, et al. Pre-existing T-and B-cell defects in one progressive multifocal leukoencephalopathy patient. PLoS One (2012) 7:e34493. doi:10.1371/journal.pone.0034493
29. Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2009) 72:396-401. doi:10.1212/01.wnl.0000327341.89587.76
30. Planas R, Jelcic I, Schippling S, Martin R, Sospedra M. Natalizumab treatment perturbs memory-and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol (2012) 42:790-8. doi:10.1002/eji.201142108
31. Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner M-P, Jilek S, et al. Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler (2012) 18:335-44. doi:10.1177/1352458511421919
32. Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 59:743-7. doi:10.1002/ana.20858
33. Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med (2014) 211:1833-46. doi:10.1084/jem.20140540
34. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol (2008) 65:1596-603. doi:10.1001/archneur.65.12.noc80051
35. de Andrés C, Teijeiro R, Alonso B, Sánchez-Madrid F, Martínez ML, Guzmán de Villoria J, et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One (2012) 7:e34103. doi:10.1371/journal.pone.0034103
36. Krzysiek R, de Goër de Herve M-G, Yang H, Taoufik Y. Tissue competence imprinting and tissue residency of CD8 T cells. Front Immunol (2013) 4:283. doi:10.3389/fimmu.2013.00283
37. Link J, Kockum I, Lorentzen AR, Lie BA, Celius EG, Westerlind H, et al. Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PLoS One (2012) 7:e36779. doi:10.1371/journal.pone.0036779
38. Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, et al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog (2014) 10:e1004084. doi:10.1371/journal.ppat.1004084
39. Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol (2014) 71:596-602. doi:10.1001/jamaneurol.2014.63
40. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol (1996) 70:7004-12.
41. Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, Sloane JA, et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol (2014) 75:925-34. doi:10.1002/ana.24148
42. Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol (2010) 63:311-7. doi:10.1159/000302687
43. Tornatore C, Berger JR, Houff SA, Curfman B, Meyers K, Winfield D, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol (1992) 31:454-62. doi:10.1002/ana.410310426
44. Warnke C, Adams O, Kieseier B. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis. JAMA Neurol (2014) 71:1192. doi:10.1001/jamaneurol.2014.1855
45. Houff SA, Berger J. The curious incident of the dog in the nighttime: does the absence of virus replication in Epstein-Barr virus-transformed B cells point to an important feature of JC virus biology? J Infect Dis (2010) 202:181-3. doi:10.1086/653824
46. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med (2012) 366:1870-80. doi:10.1056/NEJMoa1107829
47. Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf (2010) 33:969-83. doi:10.2165/11537510-000000000-00000
48. Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, et al. A second-generation ELISA (STRATIFY JCVTM DxSelectTM) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol (2013) 57:141-6. doi:10.1016/j.jcv.2013.02.002
49. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol (2010) 68:295-303. doi:10.1002/ana.22128
50. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol (2003) 84:1499-504. doi:10.1099/vir.0.18842-0
51. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 5:e1000363. doi:10.1371/journal.ppat.1000363
52. Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry (2013) 84:1199-205. doi:10.1136/jnnp-2012-304332
53. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2014) 76(6):802-12. doi:10.1002/ana.24286
54. Tur C, Montalban X. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs (2014) 28:641-8. doi:10.1007/s40263-014-0168-0
55. Jilek S, Mathias A, Canales M, Lysandropoulos A, Pantaleo G, Schluep M, et al. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 a-chain (CD11a) in MS patients. Mult Scler (2013).
56. Rothhammer V, Heink S, Petermann F, Srivastava R, Claussen MC, Hemmer B, et al. Th17 lymphocytes traffic to the central nervous system independently of a4 integrin expression during EAE. J Exp Med (2011) 208:2465-76. doi:10.1084/jem.20110434
57. Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, et al. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control. Neurology (2012) 78:458-67. doi:10.1212/WNL.0b013e3182478d4b
58. McEver RP, Zhu C. Rolling cell adhesion. Annu Rev Cell Dev Biol (2010) 26:363-96. doi:10.1146/annurev.cellbio.042308.113238
59. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 81:865-71. doi:10.1212/WNL.0b013e3182a351fb
60. Grewal IS, Foellmer HG, Grewal KD, Wang H, Lee WP, Tumas D, et al. CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis. Immunity (2001) 14:291-302. doi:10.1016/S1074-7613(01)00110-8
61. Wedepohl S, Beceren-Braun F, Riese S, Buscher K, Enders S, Bernhard G, et al. L-selectin-a dynamic regulator of leukocyte migration. Eur J Cell Biol (2012) 91:257-64. doi:10.1016/j.ejcb.2011.02.007
62. Hendel-Chavez H, de Goër de Herve M-G, Giannesini C, Mazet A-A, Papeix C, Louapre C, et al. Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy. J Virol (2013) 87:6055-9. doi:10.1128/JVI.00131-13
63. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med (2009) 361:1067-74. doi:10.1056/NEJMoa0904267
64. Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MCG, Himelfarb D, Ireland S, et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog (2012) 8:e1003014. doi:10.1371/journal.ppat.1003014
65. Miconnet I, Marrau A, Farina A, Taffé P, Vigano S, Harari A, et al. Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure. J Immunol (2011) 1950(186):7039-49. doi:10.4049/jimmunol.1003309
66. Laplaud D-A, Ruiz C, Wiertlewski S, Brouard S, Berthelot L, Guillet M, et al. Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain J Neurol (2004) 127:981-95. doi:10.1093/brain/awh119
67. Muraro PA, Bonanni L, Mazzanti B, Pantalone A, Traggiai E, Massacesi L, et al. Short-term dynamics of circulating T cell receptor V beta repertoire in relapsing-remitting MS. J Neuroimmunol (2002) 127:149-59. doi:10.1016/S0165-5728(02)00105-4
68. Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology (2013) 81:1400-8. doi:10.1212/WNL.0b013e3182a84101
69. Ma X, Zhou J, Zhong Y, Jiang L, Mu P, Li Y, et al. Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci (2014) 11:810-8. doi:10.7150/ijms.8647
70. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 79:351-79. doi:10.1146/annurev-biochem-060308-103103
71. Jr Ode F, Moore CS, Kennedy TE, Antel JP, Bar-Or A, Dhaunchak AS. microRNA dysregulation in multiple sclerosis. Front Genet (2012) 3:311. doi:10.3389/fgene.2012.00311
72. Sievers C, Meira M, Hoffmann F, Fontoura P, Kappos L, Lindberg RLP. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol (2012) 144:70-9. doi:10.1016/j.clim.2012.04.002
73. Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, et al. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler (2014) 20(14):1851-9. doi:10.1177/1352458514534513
74. Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L, et al. MiR-126: a novel route for natalizumab action? Mult Scler (2014) 20:1363-70. doi:10.1177/1352458514524998
75. Mattes J, Collison A, Plank M, Phipps S, Foster PS. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci U S A (2009) 106:18704-9. doi:10.1073/pnas.0905063106
76. Bartholdy B, Du Roure C, Bordon A, Emslie D, Corcoran LM, Matthias P. The Ets factor Spi-B is a direct critical target of the coactivator OBF-1. Proc Natl Acad Sci U S A (2006) 103:11665-70. doi:10.1073/pnas.0509430103
77. Marshall LJ, Dunham L, Major EO. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol (2010) 91:3042-52. doi:10.1099/vir.0.023184-0